BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 17121898)

  • 1. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
    Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
    Moser C; Schachtschneider P; Lang SA; Gaumann A; Mori A; Zimmermann J; Schlitt HJ; Geissler EK; Stoeltzing O
    Eur J Cancer; 2008 Jul; 44(11):1577-86. PubMed ID: 18445520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
    Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
    Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
    Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
    Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
    Adachi Y; Li R; Yamamoto H; Min Y; Piao W; Wang Y; Imsumran A; Li H; Arimura Y; Lee CT; Imai K; Carbone DP; Shinomura Y
    Carcinogenesis; 2009 Aug; 30(8):1305-13. PubMed ID: 19493905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
    Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
    Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.
    Tazzari PL; Tabellini G; Bortul R; Papa V; Evangelisti C; Grafone T; Martinelli G; McCubrey JA; Martelli AM
    Leukemia; 2007 May; 21(5):886-96. PubMed ID: 17361225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
    Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
    Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
    Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R
    Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition.
    Guerreiro AS; Boller D; Shalaby T; Grotzer MA; Arcaro A
    Int J Cancer; 2006 Dec; 119(11):2527-38. PubMed ID: 16988940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.